

ASX RELEASE

Contract update

Wellington, NZ, 5 April 2023: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global leader in software for the early detection of breast cancer, today announced that it has amended a contract with Akumin, Corp. which was [previously announced](#) to the market.

Under the terms of the amended contract, Volpara has agreed to Akumin's requested replacement of Patient Hub with Analytics. Akumin will continue to license Volpara Scorecard. Other key changes are as follows:

- Extends existing contract for 5-year term effective 1 April 2023
- Total Contract Value (TCV) of US\$1.5M
- Revenue share arrangement with additional payments of up to US\$1.25M
- Akumin termination right after year 4 in the event certain performance metrics are not met
- Installation expected within 90 days

"Volpara is thrilled to stand hand-in-hand with our valued partner, Akumin, in the fight against cancer. With the recent FDA ruling on breast density notification, Akumin is poised to utilize the power of Volpara's cutting-edge TruDensity technology, alongside our powerful Analytics product, to provide women with objective, accurate information about their breast density. Armed with this knowledge, women with dense breasts can take proactive steps to secure additional screening and early detection of cancer, helping to save more families from the devastating effects of this disease. Our Analytics product will also empower Akumin's technologists to deliver top-quality mammograms, further enhancing our joint efforts to improve women's health and well-being," says Volpara's CEO and Managing Director, Teri Thomas.

Akumin adds, "The true measure of the value of any business initiative is its impact on the lives of people. In our engagement with Volpara to improve breast cancer prevention, our top priority is the well-being and quality of life of the women we serve."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Teri Thomas, CEO
Volpara Health Technologies
teri.thomas@volparahealth.com
t: +64 4 499 6029

Hannah Howlett
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX:VHT)

Volpara Health Technologies makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 15 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A\$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com.